Utilisation de la kétamine en psychiatrie : mise à jour
Marie-Thérèse Clerc, Marcus Rosenhagen-Lapoirie, Armin Von Gunten
Revue Médicale Suisse 2022 DOI: 10.53738/revmed.2022.18.793.1626 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Key findings | The authors report that low-dose ketamine has a rapid, robust antidepressant effect via a mechanism different from conventional treatments, is included in several international recommendations for treatment-resistant depression, and is generally given intravenously or intranasally in outpatient or inpatient settings when safety requirements are met. They argue ketamine is a promising, innovative treatment, with growing interest in its use for other resistant psychiatric disorders such as anxiety and substance use disorders. |
Abstract
Ketamine has demonstrated at a lower dose a robust and rapid antidepressant effect due to a mechanism of action different from conventional treatments. It is now included in several international recommendations on treatment-resistant depression. Ketamine may be used in both out- or in-patient settings, generally by way of intravenous or intranasal formulations provided the fulfillment of safety requirements. There is a growing interest in the use of ketamine for other resistant psychiatric disorders such as anxiety and substance use disorders. Ketamine proves an innovating and promising treatment that extends the range of therapeutic possibilities in psychiatry. We propose here to review its current clinical use.
Citations in the library
Cites 12
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Journal of Affective Disorders September 23, 2020
- A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide. Psychopharmacology Bulletin March 4, 2024
- Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review BJPsych Open December 23, 2021
and 7 more in the library